Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

Isabelle Andrieux‐Meyer(Drugs for Neglected Diseases Initiative), Shahnaz Murad(Institute for Medical Research), Tim R. Cressey, François Bompart(Drugs for Neglected Diseases Initiative), Caroline Menétrey(Drugs for Neglected Diseases Initiative), Sabine Yerly(Unknown), Muhammad Radzi Abu Hassan(Hospital Sultanah Bahiyah), Anchalee Avihingsanon(Chulalongkorn University), Sombat Thanprasertsuk(Ministry of Public Health), Soek-Siam Tan(Hospital Selayang), Hajjah Rosaida Hj Mohd Said(KPJ Ampang Puteri Specialist Hospital), Nicole Ngo‐Giang‐Huong(Chiang Mai University), Alistair Swanson(Drugs for Neglected Diseases Initiative), Kanawee Thetket(Nakornping Hospital), Satawat Thongsawat(Maharaj Nakorn Chiang Mai Hospital), Wah‐Kheong Chan(University of Malaya), Bernard Pécoul(Drugs for Neglected Diseases Initiative), Nicolas Salvadori(Chiang Mai University), Vishal Goyal(Chandigarh University), Suresh Kumar(Hospital Sungai Buloh), Haniza Omar(Hospital Selayang), Sasikala Siva(Drugs for Neglected Diseases Initiative), François Simon, Hoi‐Poh Tee(Hospital Tengku Ampuan Afzan), Suparat Khemnark(Bamrasnaradura Infectious Diseases Institute)
˜The œLancet. Gastroenterology & hepatology
April 19, 2021
Cited by 42


Related Papers